abstract |
Disclosed is the use, in the manufacture of a medicament for treating BCG-resistant superficial bladder cancer in a human subject, of: i) a lyophilized composition comprising, in a citrate buffer system providing a pH of about 5 to about 6, HPbetaCD and a compound of formula I; ii) a recombinant adenoviral gene delivery system of serotype 2 having a deletion of the protein IX gene and containing a gene for a human a2b-interferon operably linked to a genetic regulatory element which modulates expression of the gene. |